Study guide
7.2 CFTR Modulator Therapies & Monitoring
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
7.2 CFTR Modulator Therapies & Monitoring
Key Takeaways Explain This Topic AI
Small-molecule CFTR modulators comprise correctors (elexacaftor, tezacaftor, lumacaftor), which overcome misfolding and facilitate endoplasmic reticulum trafficking, and potentiators (ivacaftor), which enhance apical channel open-probability (Po) for chloride and bicarbonate transport.
Elexacaftor/tezacaftor/ivacaftor (Trikafta) is approved down to 2 years of age for patients with at least one F508del mutation or responsive non-F508del mutation, producing dramatic increases in ppFEV1 (+10–14%), sweat chloride reductions of >40–50 mmol/L, and >60% fewer pulmonary exacerbations.
All CFTR modulators must be administered with fat-containing foods or beverages (target ≥20 g dietary fat, such as whole milk, eggs, peanut butter, cheese, or avocado) to ensure optimal micellar solubilization and systemic oral bioavailability (AUC increases 2- to 4-fold).
Hepatic safety monitoring requires baseline AST, ALT, and bilirubin, repeated every 3 months for the first year, then annually; therapy must be immediately interrupted if ALT or AST exceeds 5× ULN, or exceeds 3× ULN accompanied by total bilirubin >2× ULN.
Co-administration with strong CYP3A inhibitors (e.g., voriconazole, itraconazole, posaconazole) mandates drastic dose reduction (Trikafta morning dose reduced to twice weekly; evening ivacaftor omitted), while strong CYP3A inducers (rifampin, carbamazepine, phenytoin) are strictly contraindicated.
Last updated: September 2026
7.2 CFTR Modulator Therapies & Monitoring
The development of small-molecule CFTR modulators represents one of the greatest triumphs in translational precision pharmacotherapy. Unlike traditional supportive interventions that address downstream consequences (mucus retention, bacterial infection, malabsorption), CFTR modulators directly target the underlying molecular defect. By restoring transepithelial chloride and bicarbonate transport, these agents transform cystic fibrosis from a fatal childhood illness into a manageable chronic condition.
Molecular Mechanisms: Potentiators vs. Correctors
CFTR modulators are pharmacologically categorized into two distinct classes based on their molecular target and site of action: CFTR Modulator Molecular Mechanism of Action:
- ENDOPLASMIC RETICULUM APICAL CELL MEMBRANE
- ┌──────────────────────────┐ ┌─────────────────────────┐
- │ Immature / Misfolded │ │ Rescued CFTR Channel │
- │ F508del CFTR │ │ at Plasma Membrane │
- └────────────┬─────────────┘ └────────────▲────────────┘
- │ │
- ├─► [Degraded by Proteasome (Untreated)] │ Trafficking
- │ │ Rescued
- CORRECTORS │ (Elexacaftor / Tezacaftor / Lumacaftor) │
- Bind distinct allosteric pockets; promote tertiary ──────────┘
- folding & escort protein to Golgi & membrane
- POTENTIATORS (Ivacaftor)
- Binds cell-surface channel;
- holds gate open (increases Po);
- restores Cl⁻ & HCO₃⁻ efflux
- 1. CFTR Potentiators (Ivacaftor)
Prototype: Ivacaftor (VX-770; Kalydeco).
Mechanism: Ivacaftor binds directly to an allosteric transmembrane pocket on cell-surface CFTR channels. It uncouples channel gating from normal ATP hydrolysis at the nucleotide-binding domains (NBDs), locking the channel pore in an open conformation. This dramatically increases channel open probability (Po), restoring robust transepithelial chloride and bicarbonate flux in channels that are present at the plasma membrane but functionally closed (Class III gating mutations such as G551D, and Class IV conduction defects such as R117H).
2. CFTR Correctors (Lumacaftor, Tezacaftor, Elexacaftor)
Prototypes: Lumacaftor (VX-809), Tezacaftor (VX-661), and Elexacaftor (VX-445).
Mechanism: Correctors function as small-molecule pharmacological chaperones. The most common mutation, F508del, causes thermodynamic instability and abnormal domain-domain assembly (specifically between NBD1 and MSD2), causing the nascent protein to be recognized as misfolded by heat shock chaperone proteins (Hsp70/Hsp90) in the endoplasmic reticulum. This triggers rapid ubiquitination and premature proteasomal degradation.
Synergistic Dual-Corrector Action: Elexacaftor and tezacaftor bind to distinct, non-overlapping allosteric binding sites on the immature CFTR protein. Tezacaftor binds to the MSD1/NBD1 interface, whereas elexacaftor interacts with a separate hydrophobic pocket on MSD2. Their simultaneous binding produces synergistic conformational stabilization, enabling F508del CFTR to evade ER-associated degradation (ERAD), process through the Golgi apparatus, and traffic efficiently to the apical membrane.
Evolution of CFTR Modulator Regimens
Modulator Regimen Active Chemical Entities Pharmacologic Class FDA-Approved Minimum Age Approved Genotype Indications Distinguishing Pharmacologic Pearls
Ivacaftor (Kalydeco) Ivacaftor Potentiator ≥ 1 month Gating mutations (Class III: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R) and R117H Ineffective as monotherapy for F508del homozygous (no protein at membrane to potentiate); weight-based granules for infants.
Lumacaftor / Ivacaftor (Orkambi) Lumacaftor + Ivacaftor 1st-Gen Corrector + Potentiator ≥ 1 year F508del homozygous ONLY Potent CYP3A inducer (numerous severe DDIs; hormonal contraceptives fail); transient bronchospasm upon initiation.
Tezacaftor / Ivacaftor (Symdeko) Tezacaftor + Ivacaftor 2nd-Gen Corrector + Potentiator ≥ 6 years F508del homozygous OR ≥1 responsive residual function allele No CYP3A induction ; excellent tolerability without initial bronchospasm; superior DDI profile to Orkambi.
Elexacaftor / Tezacaftor / Ivacaftor (Trikafta) Elexacaftor + Tezacaftor + Ivacaftor Next-Gen Corrector + 2nd-Gen Corrector + Potentiator ≥ 2 years ≥ 1 F508del allele (homozygous or heterozygous) OR responsive mutation Unprecedented clinical efficacy: +10–14% ppFEV1, sweat chloride reduction >40–50 mmol/L, >60% drop in pulmonary exacerbations.
Clinical Impact of Triple Therapy (Trikafta)
Prior to Trikafta, patients heterozygous for F508del with a minimal function mutation (Class I, nonsense, or uncorrectable mutation on the second allele) had no approved targeted therapy because single correctors (Orkambi, Symdeko) could not traffic sufficient F508del protein to produce clinical benefit. The dual-corrector design of Trikafta rescues sufficient F508del CFTR from a single allele to generate transformative improvements: average sweat chloride levels drop by 40 to 50 mmol/L (frequently converting patients from diagnostic ≥60 mmol/L to normal <30 mmol/L), percent predicted FEV1 improves by 10 to 14 percentage points , pulmonary exacerbations decline by 63% , and body mass index (BMI) normalizes.
Administration Mandate: Dietary Fat Co-Ingestion
All small-molecule CFTR modulators (ivacaftor, lumacaftor, tezacaftor, and elexacaftor) are exceptionally lipophilic, poorly water-soluble molecules with high octanol-water partition coefficients (log P > 4.5).
Important
The Fat Co-Ingestion Rule: CFTR modulators must be consumed immediately before, during, or within 30 minutes after a fat-containing meal or snack . The target fat content is approximately ≥20 grams of fat for older children and adolescents, or a standard fat-containing meal/snack appropriate for age.
Pharmacokinetic Rationale
In the fasting state, intestinal dissolution of CFTR modulators is negligible. Dietary fat entering the duodenum triggers cholecystokinin (CCK) release, gallbladder contraction, and bile acid/phospholipid secretion, creating mixed bile salt-lecithin micelles. These micelles incorporate the lipophilic modulator molecules into their hydrophobic cores, facilitating transport across the unstirred water layer to the enterocyte brush border. Co-administration with fat increases oral bioavailability (AUC) by 2-fold to 4-fold (200% to 400%) compared to fasting. Administering modulators without fat leads to profound subtherapeutic systemic exposure and clinical therapeutic failure.
- Pediatric Dietary Fat Options
- Whole milk, whole-milk yogurt, whole-milk cheese, butter, ice cream
- Eggs (scrambled with butter or cheese)
- Peanut butter, almond butter, sunflower seed butter
- Avocados or guacamole
- Meats, salmon, oil-based salad dressings
- Commercial pediatric nutritional supplements (e.g., Pediasure, Boost, Scandishake)
For infants receiving granules: breast milk, infant formula, or whole-milk yogurt/puréed food mixed with 1 teaspoon of oil or butter.
Safety Monitoring & Organ Toxicities CFTR Modulator Comprehensive Monitoring Architecture:
- ┌────────────────────────────────────────────────────────┐
- │ LIVER FUNCTION (ALT, AST, Total & Direct Bilirubin) │
- │ • Baseline before starting │
- │ • Every 3 months for Year 1, then annually thereafter │
- │ • Interrupt if: ALT/AST >5x ULN OR >3x ULN + Bili >2x │
- └──────────────────────────┬─────────────────────────────┘
- │
- ┌──────────────────────────▼─────────────────────────────┐
- │ PEDIATRIC OPHTHALMOLOGY (Slit-Lamp Lens Examination) │
- │ • Baseline exam prior to initiation │
- │ • Periodic follow-up exams throughout pediatric growth │
- │ • Screens for non-congenital cataracts / lens opacities│
- └──────────────────────────┬─────────────────────────────┘
- │
- ┌──────────────────────────▼─────────────────────────────┐
- │ BLOOD PRESSURE & NEUROPSYCHIATRIC SURVEILLANCE │
- │ • Blood pressure at every routine clinic visit │
- │ • Screen for anxiety, depression, insomnia, brain fog │
- └────────────────────────────────────────────────────────┘
- 1. Hepatic Safety Monitoring & Dose Interruption Protocols
Transaminase elevations (ALT, AST) occur in up to 10% to 15% of patients treated with CFTR modulators, with rare progression to severe drug-induced liver injury (DILI) and hepatic failure.
Mandatory Monitoring Schedule: Measure AST, ALT, total bilirubin, and direct bilirubin at baseline , every 3 months during the first year of therapy , and annually thereafter . Patients with pre-existing hepatic impairment or history of transaminitis require monthly monitoring for the first 6 months.
Mandatory Dose Interruption Thresholds:
ALT or AST > 5 × the Upper Limit of Normal (ULN) in the absence of elevated bilirubin; OR
ALT or AST > 3 × ULN accompanied by total bilirubin > 2 × ULN .
Action: Immediately withhold all CFTR modulator therapy. Perform urgent clinical evaluation (viral hepatitis serologies, ultrasound, review of concomitant hepatotoxins). Closely track liver enzymes until they return to baseline or <2 × ULN. Re-challenging with step-wise dose escalation may be considered only if the clinical benefit outweighs the risk, under strict hepatology consultation with bi-weekly laboratory monitoring.
2. Pediatric Lens Opacities (Cataracts)
Non-congenital lens opacities and cataracts were identified in juvenile rat toxicology studies and subsequently reported in pediatric clinical trials of ivacaftor-containing regimens. Although direct causal pathogenesis remains incompletely characterized, CFTR is expressed in the ciliary body and lens epithelium.
Clinical Mandate: All pediatric patients initiating CFTR modulator therapy must undergo a baseline ophthalmologic slit-lamp examination , followed by periodic follow-up eye examinations (annually or biannually) throughout childhood to monitor for lens opacities.
3. Blood Pressure & Neuropsychiatric Surveillance
Blood Pressure: Modest increases in mean systolic and diastolic blood pressure (2 to 5 mm Hg) have been documented with elexacaftor/tezacaftor/ivacaftor. Blood pressure must be monitored at each clinic visit.
Neuropsychiatric Effects: Post-marketing pharmacovigilance highlights unexpected central nervous system effects, including anxiety, depression, insomnia, vivid dreams, and "brain fog." Clinicians must screen for psychiatric symptoms at follow-up visits; dose reduction or schedule adjustments occasionally alleviate these symptoms.
Cytochrome P450 Drug-Drug Interactions
Ivacaftor, tezacaftor, and elexacaftor are extensively metabolized by hepatic and intestinal cytochrome P450 3A (CYP3A4 and CYP3A5) enzymes. Consequently, concomitant administration with inhibitors or inducers of CYP3A dramatically alters modulator plasma concentrations. CYP3A Interaction Management for Elexacaftor/Tezacaftor/Ivacaftor (Trikafta):
Standard Dosing: Morning = 2 fixed-dose tablets (elex/tez/iva) ──► Evening = 1 ivacaftor tablet
With STRONG CYP3A Inhibitors (Voriconazole, Itraconazole, Posaconazole, Clarithromycin):
- ──► Morning: 2 fixed-dose tablets TWICE WEEKLY (Day 1 and Day 4 only)
- ──► Evening: OMITTED ENTIRELY
With MODERATE CYP3A Inhibitors (Fluconazole, Erythromycin, Grapefruit):
- ──► Morning: 2 fixed-dose tablets EVERY OTHER DAY (alternating days)
- ──► Evening: OMITTED ENTIRELY
With STRONG CYP3A Inducers (Rifampin, Carbamazepine, Phenytoin, St. John's Wort):
- ──► CONTRAINDICATED / STRICTLY AVOIDED (AUC decreases >80-90%)
- Interactions with CYP3A Inhibitors
CF patients frequently require systemic triazole antifungals ( Aspergillus fumigatus , Candida species) or macrolide antibiotics, creating profound interaction risks:
Strong CYP3A Inhibitors (e.g., voriconazole, posaconazole, itraconazole, ketoconazole, clarithromycin):
Co-administration increases modulator exposure (AUC) by up to 8- to 10-fold , precipitating transaminitis and neurotoxicity.
Trikafta Dose Adjustment: The morning fixed-dose combination (elexacaftor/tezacaftor/ivacaftor) is reduced to two tablets administered TWICE WEEKLY (e.g., Day 1 and Day 4, or Monday and Thursday). The evening ivacaftor dose is completely omitted .
Kalydeco Monotherapy Adjustment: 150 mg administered twice weekly.
Moderate CYP3A Inhibitors (e.g., fluconazole, erythromycin, ciprofloxacin [mild/moderate], grapefruit juice):
Co-administration increases modulator AUC by approximately 2- to 3-fold .
Trikafta Dose Adjustment: The morning fixed-dose combination is administered EVERY OTHER DAY (alternating days). The evening ivacaftor dose is completely omitted .
Kalydeco Monotherapy Adjustment: 150 mg administered once daily.
Interactions with CYP3A Inducers
Strong CYP3A Inducers (e.g., rifampin, rifabutin, carbamazepine, phenobarbital, phenytoin, St. John's wort):
Markedly accelerate the clearance of ivacaftor, tezacaftor, and elexacaftor, decreasing circulating plasma concentrations by >80% to 90% .
Clinical Mandate: Co-administration is strictly contraindicated . Modulator efficacy is completely abrogated, triggering severe pulmonary decompensation.
The Unique CYP Inducer Profile of Lumacaftor (Orkambi)
Unlike tezacaftor and elexacaftor, lumacaftor is a potent inducer of CYP3A4, CYP2B6, CYP2C9, and P-glycoprotein (P-gp) . When prescribing lumacaftor/ivacaftor (Orkambi):
Oral Contraceptives: Lumacaftor dramatically accelerates the hepatic clearance of ethinyl estradiol, progestins, and levonorgestrel, rendering combined oral contraceptives, patches, and implants completely ineffective . Patients must utilize alternative non-hormonal contraception (barrier methods or copper intrauterine devices).
Azole Antifungals & Immunosuppressants: Lumacaftor causes profound subtherapeutic levels of voriconazole, posaconazole, tacrolimus, and cyclosporine, precluding effective antifungal therapy and complicating solid-organ transplantation.
Practice Pearls & BCPPS Exam Traps
Exam Trap 1: If a CF patient on Trikafta develops allergic bronchopulmonary aspergillosis (ABPA) and requires oral voriconazole, do NOT maintain Trikafta at the usual daily dose. The morning combination must be reduced to twice weekly, and the evening ivacaftor dose must be discontinued.
Exam Trap 2: Do not confuse the dose adjustment for fluconazole (moderate inhibitor) with voriconazole (strong inhibitor). Fluconazole requires alternating-day dosing; voriconazole requires twice-weekly dosing. In both cases, the evening ivacaftor dose is omitted.
Board Rule: When counseling on modulator administration, always assess what fat source the family utilizes. Advising a patient to take their medication with "a glass of water and fruit" represents an immediate board failure; fat (≥20 g) is mandatory for absorption.